Incapacitating solar urticaria: successful treatment with omalizumab
Kieselova, Katarina; Santiago, Felicidade; Henrique, Martinha.
An. bras. dermatol
; 94(3): 331-333, May-June 2019. graf
Artículo
en Inglés
| LILACS | ID: biblio-1011115
Abstract Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Hereby, we report a case of solar urticaria refractory to conventional treatment strategies, with an excellent response to treatment with omalizumab and phototesting normalization.
Biblioteca responsable:
BR1.1
Texto completo
Documentos relacionados